Cell Therapy (TIL) Improves Progression-Free Survival in Advanced Melanoma, First Phase 3 Study Shows; Findings Raise Hopes for Management and Potential Cure of Metastatic Solid Tumors; May Be Practice-Changing  

A novel treatment strategy with personalized cell therapy significantly improves progression-free survival compared to standard immunotherapy in patients with advanced melanoma, according to ground-breaking results (1) from the phase 3 M14TIL trial reported on September 10 at the European Society for Medical Oncology ESMO Congress 2022 in Paris, September 9-13.The presentation was titled “Treatment with Tumor Infiltrating Lymphocytes (TIL) Versus Ipilimumab (IPI) for Advanced Melanoma: Results from a Multicenter, Randomized Phase 3 Trial.”“This study shows, for the first time in a randomized controlled trial, that cell therapy can be efficacious and beneficial for patients with solid cancers,” said lead author John Haanen, MD, PhD, Netherlands Cancer Institute, Amsterdam, Netherlands.

Login Or Register To Read Full Story